• Nicox’s first-half 2026 net loss narrowed 94% year over year to €521,000.
• Revenue more than doubled to €3.54 million, including a €3 million milestone payment from Kowa.
• Operating expenses fell 34% to €4.51 million, principally reflecting completion of the Denali trial and subsequent headcount reductions.
• Cash and cash equivalents totaled €8.4 million at August 31, 2026.
• Rights to NCX 1728 reverted to Nicox following Glaukos’s decision not to exercise its exclusive licensing option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NicOx SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610300230OMX_____CNEWS_EN_GNW1001280726_en) on October 30, 2026, and is solely responsible for the information contained therein.